Kairos Pharma, LTD. (KAPA) stock
KAPANYSEPharmaceutical PreparationsFiscal year ends December 31
$0.40−0.01 (-1.70%)
Close on Nov 17, 2026Market cap $1.49MP/E –Yield –
Kairos Pharma cash
Cash and short-term investments held at the end of each period.
Kairos Pharma's cash was $3.13M at Sep 30, 2026. For fiscal 2025 it was $4.49M, up 253.1% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.49M | +253.1% |
| FY2024 | Dec 31, 2024 | $1.27M | +1267.7% |
| FY2023 | Dec 31, 2023 | $93.00K | -78.7% |
| FY2022 | Dec 31, 2022 | $437.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.13M | -43.9% |
| Q2 FY2026 | Jun 30, 2026 | $2.63M | -13.4% |
| Q1 FY2026 | Mar 31, 2026 | $3.68M | +1.6% |
| Q4 FY2025 | Dec 31, 2025 | $4.49M | +253.1% |
| Q3 FY2025 | Sep 30, 2025 | $5.58M | +73.3% |
| Q2 FY2025 | Jun 30, 2025 | $3.03M | +14347.6% |
| Q1 FY2025 | Mar 31, 2025 | $3.62M | +8940.0% |
| Q4 FY2024 | Dec 31, 2024 | $1.27M | +1267.7% |
| Q3 FY2024 | Sep 30, 2024 | $3.22M | +3149.5% |
| Q2 FY2024 | Jun 30, 2024 | $21.00K | -95.2% |
| Q1 FY2024 | Mar 31, 2024 | $40.00K | – |
| Q4 FY2023 | Dec 31, 2023 | $93.00K | – |
| Q3 FY2023 | Sep 30, 2023 | $99.00K | – |
| Q4 FY2022 | Dec 31, 2022 | $437.00K | – |
See a number that looks wrong?